Zhou C - Search Results

1

Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.

Wu YL, Lu S, Cheng Y, Zhou C, Wang M, Qin S, Lu Y, Zhang Y, Zhu Y, Song X, Wang X, Barraclough H, Zhang X, Chi H, Orlando M. Wu YL, et al. Among authors: zhou c. Lung Cancer. 2014 Sep;85(3):401-7. doi: 10.1016/j.lungcan.2014.07.007. Epub 2014 Jul 17. Lung Cancer. 2014. PMID: 25082564 Clinical Trial.

2

Effects of collagen iv on cisplatin-induced apoptosis of non-small cell lung cancer cells.

Su C, Su B, Tang L, Zhao Y, Zhou C. Su C, et al. Among authors: zhou c. Cancer Invest. 2007;25(7):542-9. doi: 10.1080/07357900701513272. Cancer Invest. 2007. PMID: 17952737

3

Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.

Zhou S, Ren S, Yan L, Zhang L, Tang L, Zhang J, Zhou C. Zhou S, et al. Among authors: zhou c. Respirology. 2009 Jul;14(5):709-15. doi: 10.1111/j.1440-1843.2009.01564.x. Respirology. 2009. PMID: 19659649 Clinical Trial.

4

BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.

Li Z, Zhou S, Zhang L, Su C, Hang J, Zhao Y, Su B, Zhou C. Li Z, et al. Among authors: zhou s, zhou c. Med Oncol. 2011 Jun;28(2):572-7. doi: 10.1007/s12032-010-9470-y. Epub 2010 Mar 17. Med Oncol. 2011. PMID: 20237869

5

ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.

Su C, Zhou S, Zhang L, Ren S, Xu J, Zhang J, Lv M, Zhang J, Zhou C. Su C, et al. Among authors: zhou s, zhou c. Med Oncol. 2011 Dec;28(4):1411-7. doi: 10.1007/s12032-010-9553-9. Epub 2010 May 14. Med Oncol. 2011. PMID: 20467918

6

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, Zhou C, Zhang J. Ren S, et al. Among authors: zhou s, zhou c. Cancer Invest. 2010 Dec;28(10):1078-83. doi: 10.3109/07357901003735659. Epub 2010 May 26. Cancer Invest. 2010. PMID: 20504223 Clinical Trial.

7

Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.

Su C, Zhou C, Zhou S, Xu J. Su C, et al. Among authors: zhou c, zhou s. Med Oncol. 2011 Dec;28(4):1453-7. doi: 10.1007/s12032-010-9645-6. Epub 2010 Aug 17. Med Oncol. 2011. PMID: 20714944

8

[Relationship between ERCC1 expression and efficacy of neoadjuvant chemotherapy in the patients with non-small-cell lung cancer.].

Zhou S, Zhou C, Xu Q, Yan L. Zhou S, et al. Among authors: zhou c. Zhongguo Fei Ai Za Zhi. 2008 Apr 20;11(2):251-5. doi: 10.3779/j.issn.1009-3419.2008.02.030. Zhongguo Fei Ai Za Zhi. 2008. PMID: 20731911 Free article. Chinese.

9

Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.

Mok T, Wu YL, Au JS, Zhou C, Zhang L, Perng RP, Park K. Mok T, et al. Among authors: zhou c. J Thorac Oncol. 2010 Oct;5(10):1609-15. doi: 10.1097/JTO.0b013e3181e15d55. J Thorac Oncol. 2010. PMID: 20808255 Free article. Clinical Trial.

10

Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Ju L, Zhou C, Li W, Yan L. Ju L, et al. Among authors: zhou c. J Cell Biochem. 2010 Dec 15;111(6):1565-74. doi: 10.1002/jcb.22888. J Cell Biochem. 2010. PMID: 21053345

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21,123 results

Search Page

Filters